Agarikon

Metadata

Regulatory Status

Historical (No Longer Active)

• US Pharmacopoeia: Agaric acid listed as antisecretory/anhidrotic agent for tubercular night sweats (19th-early 20th century). Dose: 5-15 mg. Removed when synthetic alternatives became available.
• British Pharmacopoeia: Similarly listed and subsequently removed.
• Western pharmacy tradition: ~1,800 continuous years in pharmacopoeias from Dioscorides through 20th century.

Current

• United States: Mycelium-based supplements available under DSHEA (e.g., Host Defense Agarikon, Fungi Perfecti)
• No FDA GRAS or pharmaceutical status
• No formal regulatory status in any current jurisdiction
• DARPA/BioShield: Stamets’ research conducted partly under government biodefense contract

Conservation Status

• Endangered in Europe: Listed as endangered, critically endangered, or regionally extinct in many European countries (UK, Germany, France, Sweden, Norway, Switzerland, Austria)
• IUCN: Assessment status uncertain; recognized as one of the most endangered macrofungi in Europe
• Habitat: Exclusively parasitic on old-growth conifers (primarily larch, also fir, spruce); requires trees >100 years old
• Growth rate: Individual conks may persist for decades to centuries (50-75+ years for a large specimen)
• Strongholds: Pacific Northwest North America (BC, Alaska, WA, OR) retains healthy populations in remaining old-growth forests
• Wild harvest is ethically and ecologically problematic; cultured mycelium should be used exclusively

Historical Significance: The Dioscorides Connection

Agarikon has a unique place in the history of mycological medicine:

1. Dioscorides, De Materia Medica (~65 AD): First known detailed pharmacological description of a specific fungal medicine in Western literature. Described “agarikon” for phthisis (tuberculosis), fevers, and internal ailments. Named after Agaria in Sarmatia (modern southern Russia/Ukraine).

2. Continuous pharmacopoeial tradition: From Dioscorides through Galen (~170 AD), Avicenna (~1025 AD), Renaissance herbalists (Gerard 1597, Culpeper), and into 19th-century USP/BP — an unbroken ~1,800-year pharmaceutical presence. Very few natural medicines can claim such longevity.

3. The tuberculosis thread: The most persistent specific indication from antiquity through the 19th century. Stamets’ finding of anti-mycobacterial activity in vitro is a striking potential validation.

4. Pacific Northwest indigenous use: Tlingit, Haida, and other coastal groups used agarikon for respiratory infections, wounds, and ceremonial purposes. Some groups carved conks into spirit figures (Blanchette et al., 1992).

5. Decline: Fell from Western pharmacy in the early 20th century as synthetic drugs replaced botanicals, anti-TB chemotherapy transformed treatment (streptomycin 1944, isoniazid 1952), and old-growth larch forests were progressively logged.

Conditions & Indications

Primary (Historical + In Vitro)

• Respiratory infections / Tuberculosis — 2,000 years of documented use for pulmonary conditions; Stamets’ in vitro screening showed activity against M. tuberculosis; chlorinated coumarins with antibacterial activity (Hwang et al., 2013).
• Antiviral (broad-spectrum) — Stamets/Fungi Perfecti/DARPA screening: mycelial extracts showed potent in vitro activity against orthopoxviruses (cowpox as smallpox surrogate) and influenza H5N1. Activity was strain-dependent with >10-fold variation between strains.
• Fever / Antipyretic — Historical use by Dioscorides, Pliny, Galen, Avicenna. “Quinine Conk” name reflects antipyretic use by analogy (different mechanism from quinine).

Secondary (Historical)

• Night sweats (antisecretory) — Agaric acid was specifically used for tubercular night sweats; USP-listed indication
• Purgative/cathartic — One of the primary historical uses; dose-dependent GI effect
• Wound infections (antimicrobial) — Pacific Northwest indigenous use

Emerging/Preclinical

• Anti-inflammatory — Lanostane triterpenoids inhibit NF-kB and COX-2
• Antitumor — Very preliminary polysaccharide immunostimulatory and triterpenoid cytotoxic screening

Mechanism of Action

Primary Mechanisms

1. Chlorinated coumarin antimicrobial activity: Unique class not found in other medicinal fungi. Hwang et al. (2013) isolated novel chlorinated coumarins with antibacterial activity against S. aureus and B. subtilis (MIC in low micromolar range). Chlorine substitution on the coumarin ring appears critical for bioactivity.

2. Lanostane triterpenoid anti-inflammatory activity: Eburicoic acid and dehydroeburicoic acid inhibit NF-kB nuclear translocation, 5-LOX, and COX-2, reducing prostaglandin and leukotriene synthesis. Also show direct antimicrobial activity against Mycobacterium species in vitro.

3. Polysaccharide immunostimulation: Beta-1,3/1,6-D-glucans activate Dectin-1/TLR2/CR3 pathways (shared across medicinal mushrooms), enhancing macrophage phagocytic activity and NK cell cytotoxicity.

4. Agaric acid pharmacology:

   • Antisecretory/anhidrotic: Inhibits cholinergic signaling to sweat glands (explaining night sweat indication)
   • Cathartic/purgative: GI irritant at higher doses (dose-limiting side effect)
   • Antipyretic: Incompletely characterized mechanism, possibly involving prostaglandin synthesis inhibition
   • Historical pharmaceutical use: agaric acid content ~10-15% of mature fruiting body dry weight (Petrova et al., 2007)

Pharmacological Note

Agarikon’s chemical profile is notably different from most commercial medicinal mushrooms. While others are primarily characterized by polysaccharides and/or triterpenoids, agarikon is distinguished by: (1) agaric acid — a unique fatty acid derivative, (2) chlorinated coumarins, and (3) diverse lanostane triterpenoids. This unusual chemical diversity may account for its historically broad therapeutic applications and Stamets’ observation of strain-specific antiviral activity.

Clinical Evidence Summary

CRITICAL: No Human Clinical Trials Exist

The evidence base consists of:

1. ~2,000 years of documented traditional use
2. In vitro antimicrobial/antiviral screening data (primarily Stamets/Fungi Perfecti)
3. Limited published phytochemical and pharmacological studies
4. Ethnomycological documentation

Key Research

Evidence Limitations

• No human clinical trials — the most critical limitation
• Much of Stamets’ data was generated under government contract (DARPA) and not fully published in peer-reviewed journals
• Dramatic strain-to-strain variation complicates standardization
• Conservation constraints limit research access to wild fruiting bodies
• Taxonomic confusion across historical reclassifications
• Traditional evidence cannot distinguish efficacy from placebo or spontaneous resolution

Safety Profile

General Assessment

2,000-year history of human use; serious adverse effects not prominent in historical record. Primary safety concern is dose-dependent purgative effect of agaric acid. No formal toxicology studies.

Contraindications

• GI sensitivity (agaric acid is a potent cathartic at higher doses)
• Pregnancy and lactation (no data)
• Hepatic impairment (insufficient data)
• Children (no data)

Drug Interactions

• No clinically documented interactions
• Theoretical: anti-inflammatory triterpenoids may have additive effects with NSAIDs/corticosteroids; immunostimulatory polysaccharides may antagonize immunosuppressants
• Risk assessed as low but reflects absence of data, not demonstrated safety

Side Effects

• GI effects: The most consistently reported adverse effect across 2,000 years. Agaric acid causes dose-dependent nausea, cramping, and diarrhea. Historical preparations carefully controlled dosage.
• Other: No consistent reports of other adverse effects

Toxicology

• No formal LD50 data
• No mutagenicity or carcinogenicity data
• Historical removal from USP/BP was based on GI tolerability, not serious toxicity

Clinical Dosage

Historical (No Longer Standard)

• Dried fruiting body powder: 0.3-2 g/day (historical European pharmacy)
• Agaric acid (isolated, USP historical): 5-15 mg for night sweats
• Historical doses were much lower than modern mushroom supplements, reflecting agaric acid potency

Modern Supplement (Mycelium)

• Host Defense Agarikon (Fungi Perfecti): ~1 g/day mycelium biomass (2 capsules)
• No clinical trial supports any specific modern dosage
• Dual extraction (hot water + ethanol) recommended to capture full spectrum

Conservation Ethics

• Wild harvest is ethically and ecologically problematic given endangered status
• Only cultured mycelium or sustainably sourced material should be used
• Stamets maintains a culture collection of diverse strains at Fungi Perfecti

Sources

Historical

• Dioscorides. De Materia Medica. ~65 AD. Book III, Chapter 1
• Pliny the Elder. Naturalis Historia. ~77 AD. Book XXV
• Galen. De Simplicium Medicamentorum. ~170 AD
• Avicenna. Canon of Medicine. ~1025 AD
• Gerard J. The Herball or Generall Historie of Plantes. 1597

Modern Research

• Stamets P. Mycelium Running: How Mushrooms Can Help Save the World. Ten Speed Press, 2005
• Hwang CH, et al. Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis. J Nat Prod. 2013;76(12):2282-2286
• Grienke U, et al. European medicinal polypores — a modern view on traditional uses. J Ethnopharmacol. 2014;154(3):564-583
• Petrova A, et al. Lipophilic compounds from Fomitopsis officinalis. Pharmazie. 2007;62(12):940-942

Ethnomycological

• Blanchette RA, et al. Nineteenth century shaman grave guardians are carved Fomitopsis officinalis sporophores. Mycologia. 1992;84(1):119-124
• Turner NJ. Food Plants of Coastal First Peoples. Royal BC Museum, 1995

Conservation

• Dahlberg A, Croneborg H. 33 Threatened Fungi in Europe. Council of Europe, 2003

Connections

• Fills the respiratory therapeutic category — the only candidate with deep historical record specifically for pulmonary conditions
• Compare with Turkey Tail: pharmaceutical-grade evidence (PSK) vs. agarikon’s purely preclinical stage illustrates the vast gap between ethnomycological documentation and clinical validation
• Beta-glucan immunostimulatory mechanism is shared with other medicinal mushrooms, but agarikon’s chlorinated coumarins and agaric acid are unique
• Compare with Chaga — both slow-growing, wild-harvested with conservation concerns; both raise sustainability questions
• The Dioscorides lineage (~65 AD) makes agarikon one of two oldest documented medicinal fungi alongside Birch Polypore (Otzi, ~3300 BC)
• Siberian folk medicine connects agarikon (eburiko) with Chaga — both boreal forest fungi used for respiratory and tonic purposes